Does honey provide therapeutic relief to patients with chemotherapy induced oral mucositis? by Grugan, Jennifer
Philadelphia College of Osteopathic Medicine 
DigitalCommons@PCOM 
PCOM Physician Assistant Studies Student 
Scholarship Student Dissertations, Theses and Papers 
2021 
Does honey provide therapeutic relief to patients with 
chemotherapy induced oral mucositis? 
Jennifer Grugan 
Philadelphia College of Osteopathic Medicine 
Follow this and additional works at: https://digitalcommons.pcom.edu/pa_systematic_reviews 
 Part of the Medicine and Health Sciences Commons 
Recommended Citation 
Grugan, Jennifer, "Does honey provide therapeutic relief to patients with chemotherapy induced oral 
mucositis?" (2021). PCOM Physician Assistant Studies Student Scholarship. 602. 
https://digitalcommons.pcom.edu/pa_systematic_reviews/602 
This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student 
Dissertations, Theses and Papers at DigitalCommons@PCOM. It has been accepted for inclusion in PCOM 
Physician Assistant Studies Student Scholarship by an authorized administrator of DigitalCommons@PCOM. For 
more information, please contact library@pcom.edu. 
Does honey provide therapeutic relief to patients with chemotherapy 








Jennifer Grugan, PA-S  
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW 
In Partial Fulfillment of the Requirements For  
The Degree of Master of Science 
In 
Health Sciences – Physician Assistant 
 
 
Department of Physician Assistant Studies 



























OBJECTIVE: The objective of this selective EBM review is to determine whether or not “does 
honey provide therapeutic relief to patients with chemotherapy induced oral mucositis?”  
 
STUDY DESIGN: Review of one double-blind randomized control trial (RCT), one RCT, and 
one cohort study.  
 
DATA SOURCES: All articles were published in English and taken from peer-reviewed 
journals using PubMed. All articles were published between 2012-2019.  
 
OUTCOMES MEASURED: The outcomes measured included decreased severity of oral 
mucositis measured in one study using the WHO Oral Toxicity Scale and another using WHO-
STC (Stomatitis Toxicity Criteria). Another outcome measured was recovery time, which was 
defined as the number of days from the start of treatment to when complete healing of every 
ulcer occurred.  
 
RESULTS: The double-blind RCT performed by Raeessi et al. showed a statistically significant 
difference (p-value<0.001) after treatment with honey when compared to the steroid group. The 
mean severity of oral mucositis (OM) was 1.43±  0.75  after treatment with the steroid compared 
to 0.90 ± 0.65 after treatment with honey. The mean difference between the honey and control 
group was 0.51. Abdulrhman et al. conducted a RCT that showed a statistically significant 
difference (p-value <0.005) between the mean recovery time (days) of children with OM in the 
benzocaine group vs. the honey group.  For the benzocaine group, the recovery time mean was 
6.10±2.47. The honey group recovery time mean was 4.25±1.25. The mean difference between 
the two groups was 1.85. The cohort study performed by Singh et al. showed a statistically 
significant reduction (p-value<0.01) in the severity of OM by day 7 between the control group 
and the experimental honey group. By day 7, 27 (54%) children had Grade 0 OM in the control 
group, while 46 (92%) children had Grade 0 OM in the honey group. The calculated NNT was 3, 
the ABI was 0.38, and the RBI was 0.70.  
 
CONCLUSION: All three studies demonstrated that honey provides a statistically significant 
decrease in severity of OM and recovery time, demonstrating the therapeutic relief honey 
provides to patients with chemotherapy induced OM.  
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INTRODUCTION 
 
Oral mucositis (OM) is one of the most common and recurrent side effects of 
chemotherapy treatment. OM results from breakdown of the oral mucosal lining, leading to ulcer 
formation. Before ulcer formation occurs, endothelial cells become damaged and inflammatory 
cytokines and reactive oxygen species are activated at the mucosal level.1,2 Between 40-80% of 
chemotherapy patients suffer from OM, which can adversely affect speech and nutrition and 
result in malnutrition and dehydration.1,2 Patients who develop OM can also develop infections 
that require prolonged hospital stays. This increases treatment costs and may require clinicians to 
modify chemotherapy treatment protocols and doses for their patients.  
Unfortunately, this common side effect of chemotherapy is often overlooked by clinical 
treatment teams who are capable of preventing and treating this condition.1,2 Studies show that 
the estimated incremental cost of OM per cycle of chemotherapy is $3,700.3 While it is unknown 
how many healthcare visits are associated with this condition each year, one study showed that in 
a population of cancer patients receiving chemotherapy, the average rate of hospitalization was 
one admission per year with 40% of admissions identified as being related to a chemotherapy 
issue.4 
Often appearing 7-14 days after initiation of chemotherapy, OM results in erythema, 
edema, an ulceration that creates a burning sensation, or the development of painful ulcers that 
can impact oral function. OM usually resolves in 2-3 weeks after a chemotherapy infusion.1,2  
OM has a complex pathobiology on how oral mucosa damage occurs as a result of 
chemotherapy. Risk factors for the development of OM include younger age, poor oral hygiene, 
and the nutritional status of a patient.2 Chemotherapy drugs that commonly cause OM include 
methotrexate, etoposide, cytarabine, fluorouracil, and doxorubicin.2 Some of the usual methods 
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used to treat OM include oral hygiene protocols (frequent brushing/flossing), antimicrobial 
agents (chlorhexidine), local anesthetics (benzocaine), and steroids (betamethasone).1,2,5,6 More 
recently oral cryotherapy, where ice chips are used to cool mucous membranes during infusions, 
is a readily available treatment intervention.7 
While methods exist to address this condition, few efficacious interventions are available 
for management of chemotherapy induced OM. There is currently no specific, single standard 
method to prevent and treat OM.1 As a result, research has been investigating the impact of 
honey on OM. Honey, which is produced by honeybees (Apis mellifera), has H2O2, which is 
produced by glucose oxidase and attributes to honey’s antimicrobial property.5 Honey can reduce 
inflammation and accelerate tissue regeneration, which explains its therapeutic use in treating 
conditions such as gingivitis and periodontal disorders.5 This paper analyzes one double-blind 
RCT, one RCT, and one cohort study to evaluate the therapeutic relief honey provides for 
chemotherapy induced OM.  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not “does honey 
provide therapeutic relief to patients with chemotherapy induced oral mucositis?”  
METHODS 
The population targeted for this review included patients with chemotherapy induced oral 
mucositis (OM). The intervention being investigated for therapeutic relief of oral mucositis is 
honey in comparison to benzocaine gel, betamethasone steroid, and analgesic/antiseptic gel 
(choline salicylate 8.7% w/w + benzalkonium 0.01% w/w + lignocaine HCL 2.0% w/w). The 
outcomes being measured are decreased severity of oral mucositis and recovery time. All articles 
were published in English in peer-reviewed journals between 2012-2019 and obtained from 
PubMed. The articles were selected based on relevance and if they included patient oriented 
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outcomes. Keywords used to obtain the articles included “honey” and “oral mucositis”. Inclusion 
criteria were articles published in the last 10 years in English that involved humans. Exclusion 
criteria included systematic reviews and research published before 2012. A summary of statistics 
reported includes p-values, NNT, RBI, and ABI. The studies included in this EBM review 
include a double blind RCT, a RCT, and a cohort study. Table 1 includes demographics and 
characteristics of the included studies.  
Table 1. Demographics & Characteristics of Included Studies 
Study Type # Pts Age 
(yrs) 
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OUTCOMES MEASURED 
 
The outcomes measured in this EBM review included decreased severity of oral 
mucositis measured using the WHO Oral Toxicity Scale and the WHO-STC (Stomatitis Toxicity 
Criteria), as well as recovery time that was defined as the number of days from the start of 
treatment to when complete healing of all ulcers occurred.6 The WHO scales grade OM in the 
following manner: Grade 0 (none) None, Grade 1 (mild) oral soreness, erythema, Grade 2 
(moderate) erythema, ulcers, solid diet tolerated, Grade 3 (severe) oral ulcers, liquid diet only, 
Grade 4 (life-threatening) oral feeding is impossible, requires parental nutrition.1,5 
RESULTS 
 
Raeessi et al. conducted a double-blind RCT that compared the effects of oral honey and 
betamethasone in adults with chemotherapy induced OM. A total of 75 participants (15-80 years 
old) with chemotherapy induced OM during a period of three years at Baqiyatallah University 
Hospital in Tehran, Iran were selected for this study between 2012-2013.5 Individuals were 
chosen based on specific inclusion and exclusion criteria noted in Table 1. Participants were 
randomized using an online statistical computing web programming into two groups-one group 
receiving the steroid betamethasone and another group receiving oral honey.5 In order to keep 
consistency between all three studies, this review will not discuss the third comparison 
intervention measured in this study. The treatments for each group were encoded confidentially 
and distributed randomly to participants. Participants were instructed to sip and swallow 3 
teaspoons of their prescribed treatment and were asked to repeat this process every three hours 
for one week.5 There were 13 participants who were lost to follow up or discontinued the 
intervention, leaving 62 participants left to be analyzed at completion of the study. The losses 
were equal across each studied group.5   
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Severity of OM was clinically evaluated before treatment and one week after the 
intervention began. Five physicians categorized participants on the basis of the WHO Oral 
Toxicity Scale for grading OM. Grading was assigned on a scale of 0-3 (0=no OM, 1=mild, 
2=moderate, 3=severe), and was used as the main outcome measurement to compare the 
effectiveness of the interventions.5 Table 2 depicts the changes in the mean of OM severity and 
standard deviation (± STD) before and after treatment for each intervention. A statistically 
significant difference after treatment was measured as a p-value <0.001 between interventions.5 
For the steroid group, the mean severity of OM was 2.52 ± 0.51 before treatment and 1.43±  0.75  
after treatment, with a mean difference of 1.09.5 For the honey group, the mean severity of OM 
was 2.50 ±0.51 before treatment and 0.90 ± 0.65 after treatment, with a mean difference of 1.60.5 
The mean difference between the honey and control group was 0.51.5 This study did not discuss 
adverse events, safety concerns, or tolerability among its participants.   
Table 2. WHO Oral Toxicity Scale Mean± STD Change in Severity of OM Before and 
After Treatment and Statistical Significance5 










2.52± 0.51 1.43± 0.75 1.09 0.001 
Honey 
Group 
2.50± 0.51 0.90± 0.65 1.60 
Both 
groups 
 0.51  
 
Abdulrhman et al. conducted a RCT that compared the effects of topical honey and 
benzocaine gel in children with chemotherapy induced OM. A total of 90 children (2-18 years 
old) with acute lymphoblastic leukemia (ALL) and chemotherapy induced OM (grade 2 and 3) 
were selected for this study. Children were recruited from the Hematology-Oncology Unit of 
Children’s Hospital of Ain Shams University in Egypt from 2010-2011.6 Children were chosen 
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based on the inclusion and exclusion criteria noted in Table 1. Children were admitted to the 
hospital during the study period to avoid follow-up loss and ensure compliance. Children were 
randomized into two groups-one group received benzocaine 7.5% gel three times daily and 
another group received 0.5g honey/kg applied topically to the oral mucosa three times daily until 
healing occurred or for 10 days, which is usually the maximum healing time frame for OM.6 In 
order to keep consistency between all three studies, this review will not discuss the third 
comparison intervention measured in this study. All children received routine oral care (tooth 
brushing followed by a saline rinse three times daily) and were followed up daily.6 Application 
of both treatments was applied by a resident or nursing staff member under researcher 
supervision.6 The outcome measured was recovery time, which was defined as the number of 
days from the start of treatment to when complete healing of OM occurred.6 No children were 
lost to follow up for this study and all topical treatments were tolerated with no gastrointestinal 
adverse effects or hypersensitivity reaction.6  
Table 3 depicts the mean recovery time (days) and standard deviation (± STD) for both 
interventions for children with grade 2 and 3 OM. A statistically significant difference was 
measured as a p-value <0.005 between interventions.6 For the benzocaine group, the recovery 
time mean was 6.10±2.47. The honey group had a recovery time mean of 4.25±1.25. The mean 
difference between the two groups was 1.85.6  
Table 3. Recovery Time Mean± STD in Children with Chemotherapy Induced OM and 
Statistical Significance6 
 Recovery time (days) 






6.10±2.47  0.005 
Honey Group 4.25±1.25 
Both Groups  1.85  
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Singh et al. was a cohort study that compared topical honey to a routine practice of 
analgesic and antiseptic gel in children with chemotherapy induced OM. A total of 100 children 
from the Hematology-Oncology Unit at APC, PGIMER, Chandigarh were selected for this study 
in India.1 Children were selected based on specific inclusion and exclusion noted in Table 1. 
Two groups (experimental and control) with 50 children in each were identified, with the 
outcome of the study assessed by a blinded observer who assessed the severity of OM using the 
WHO-STC scale every other day until cure in both groups.1 The experimental group received 
topical honey while the control group received a routine practice of analgesic and antiseptic gel. 
Caregivers of the children were trained through demonstration on how to apply topical honey on 
OM.1 Caregivers applied 1-2mL of honey four times daily from the start of the study until cure 
of OM.1 The control group only received the analgesic and antiseptic gel. No children were lost 
to follow up. 
 This EBM review will focus on the results of day 7. On the 7th day there was a 
statistically significant reduction in the severity of OM with a measured p-value<0.01.1 As 
shown in Table 4, by day 7, 27 (54%) children had Grade 0 OM in the control group, while 46 
(92%) children had Grade 0 OM in the experimental honey group. The calculated NNT was 3, 
which showed a large treatment effect that implies clinical significance. The ABI was 0.38 and 
the RBI was 0.70 as shown in Table 5. No adverse effects, tolerability, or safety concerns were 
mentioned in this study.  
Table 4. Number of Children with Grade 0 OM on Day 7 in Both Groups and Statistical 
Significance1 
Control group n (%) Experimental group n (%) P-value  
27(54) 46(92) 0.01 
 
Table 5. Calculations for Treatment from Singh et al.1  
Study CER EER RBI ABI NNT 
Singh et al. 0.54 0.92 0.70 0.38 3 
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DISCUSSION 
 
OM can be a debilitating condition for those who are battling cancer. The goal of this 
systematic review was to determine if honey provided therapeutic relief to patients with 
chemotherapy induced OM. All three articles reviewed demonstrated a significant improvement 
of OM with the use of honey. For Raeessi et al. there was a significant difference (p<0.001) in 
the mean severity of OM between the steroid group (2.52 ± 0.51 before treatment and 1.43±  
0.75  after treatment) and the honey group (2.50 ±0.51 before treatment and 0.90 ± 0.65 after 
treatment), meaning that honey reduced the severity of OM in adults more than the use of the 
steroid.5 The mean change from baseline difference between both groups was 0.51, 
demonstrating a large treatment effect in favor of honey. 
Singh et al. and Abdulrhman et al. both demonstrated the positive impact of honey on 
OM in children. Abdulrhman et al. demonstrated that there was a statistically significant 
difference (p<0.005) between interventions in their mean recovery time. The mean recovery time 
for the benzocaine group was 6.10 days, while the honey group had a recovery time mean of 4.25 
days. The mean difference was 1.85 days, which shows that honey produced faster healing of 
Grade 2 and 3 OM than the use of benzocaine.6 Singh et al. focused on children with Grade 1 
and 2 OM. By day 7, 54% of children in the control group had Grade 0 OM compared to 92% 
from the experimental honey group, demonstrating a statistical significant difference (p<0.01) 
between both groups in terms of decreased severity of OM with honey providing the most 
improvement.1 The treatment effect of honey was large, with NNT=3.  
One limitation for Singh et al. was there was no intention-to-treat analysis and the 
children were not blinded to their treatment or randomized. The study also excluded children 
with DM.1 There was also a disparity between the control and experimental group on the 1st day 
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of enrollment. In the experimental group, 96% of children had grade II OM compared to 78% in 
the control group, demonstrating that from the first day of enrollment there were children with a 
more severe grade of OM in the experimental group compared to the control group.1 Limitations 
for Abdulrhman et al. and Raeessi et al. also existed due to the exclusion of participants with 
certain preexisting conditions as noted in Table 1. Abdulrhman et al. also states that the better 
distribution and amount of honey used in the oral cavity could have contributed to its outcome.6 
The benefit to this intervention is that honey is widely available to all at any local grocery store 
and is cost-effective. The one drawback to this intervention would be that it would not be 
recommend to those who have had allergic reactions to honey in the past.  
CONCLUSION  
 
All three studies in this EBM review demonstrated that honey provides therapeutic relief 
to patients with chemotherapy induced OM. Future studies could include incorporating more 
patients who have concurrent systemic diseases to assess if the impact of honey differs for those 
who also suffer from additional co-existing medical conditions and enhance generalizability. 
Future studies can be designed to include stratified random sampling to ensure both groups being 
studied have a more equal, comparable severity grade of OM at baseline to further strengthen the 
significance of the results. A more recent study has demonstrated that not only can use of a 
honey mouthwash decrease OM severity, but it can also reduce the possibility of weight loss and 
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